13 results about "Inflammatory molecules" patented technology

The application relates to the field of biotechnology, in particular to a Faecalibacterium prausnitzii microbial anti-inflammatory molecule and a screening method and application thereof. The amino acid sequence of the Faecalibacterium prausnitzii microbial anti-inflammatory molecule is shown in (a) or (b); (a) the amino acid sequence is shown in SEQ ID NO. 1; (b) a protein derived from (a) with anti-inflammatory activity obtained by substituting, deleting or adding one or more amino acids in the amino acid sequence in (a). Compared with the microbial anti-inflammatory molecule protein of a representative strain A2-165 of the Faecalibacterium genus, the inhibiting effects of the Faecalibacterium prausnitzii microbial anti-inflammatory molecule on the NF-kappa B signal pathway and the inflammatory factor TNF alpha are 50% and 56% respectively, and the anti-inflammatory effect (inhibiting the NF-kappa B signal pathway) of the Faecalibacterium prausnitzii microbial anti-inflammatory molecule screened in the application can reach more than 90%, and the Faecalibacterium prausnitzii microbial anti-inflammatory molecule has the advantages of small use dosage and strong anti-inflammatory effect.

The application discloses a method for stably producing exosomes of regenerative repair and anti-inflammatory molecules of sheep umbilical cord mesenchymal stem cells and application thereof in skin care products, and comprises the following steps: S1, using healthy sheep umbilical cord as raw material, obtaining primary sheep umbilical cord mesenchymal stem cells through aseptic treatment, Wharton's jelly extraction and tissue block adherent culture; S2, introducing an immortalization gene into the primary sheep umbilical cord mesenchymal stem cells through a lentivirus transduction technology, and obtaining an immortalized sheep umbilical cord mesenchymal stem cell line through resistance screening; S3, collecting supernatant after amplification culture of the immortalized sheep umbilical cord mesenchymal stem cell line, and purifying through multi-stage centrifugal impurity removal and PEG precipitation method to obtain stably produced exosomes containing regenerative repair and anti-inflammatory molecules. The exosomes containing regenerative repair and anti-inflammatory molecules provided by the application exhibit significant advantages in yield and quality, and have outstanding application value in the fields of medical beauty anti-aging and skin care products.

The invention belongs to the technical field of biological medicines, and particularly relates to application of a Tim-4 functional structural domain-based macrophage targeted nanomaterial combined intestinal selective biological preparation in inflammatory bowel diseases. Specifically, according to the macrophage targeting nano material based on the Tim-4 functional structural domain, through precise delivery of anti-inflammatory molecules and combination with a clinical drug (vializumab), dual regulation and control of innate immunity and adaptive immunity are achieved, so that the inflammatory bowel disease is efficiently treated, and therefore the macrophage targeting nano material has good practical application value.

This invention discloses a hemostatic crystalloid material, its preparation method, and its applications, relating to the field of biomedical materials. The hemostatic crystalloid material of this invention includes a crystalloid carrier and anti-inflammatory molecules, analgesic molecules, and inorganic nanofillers loaded on the crystalloid carrier. The hemostatic crystalloid material exhibits a multilayered, dense porous structure with pore sizes ranging from 10 to 300 μm and an average pore size of 100 to 200 μm. The porosity of the hemostatic crystalloid material is 60-99%, and its density is 0.001-0.1 g / mm³. 3 The surface potential of the hemostatic crystal gel material is -100 to 0 mV. This invention utilizes the reversible dynamic covalent Schiff base formed by the condensation of oxidized hyaluronic acid and chitosan derivatives with aldehyde and amino groups at low temperature, resulting in a shape memory crystal gel with a connected porous structure capable of rapid hemostasis.

A small molecule TNF-α inhibitor is disclosed. The compound has an activity of inhibiting the formation of a TNF-α homotrimer by specifically binding to the binding cavity of a TNF-α homodimer. A composition containing the compound as well as uses of the compound and the composition in preventing or treating autoimmune diseases and / or inflammatory diseases are disclosed. Extracellular inactivation of TNF-α through protein-protein interface destruction is the most innovative and effective method for alleviating chronic systemic inflammatory states, and TIM series compounds, which have better efficacy and lower toxicity than those of existing TNF inhibitors and have oral bioavailability, can be effectively used as leading anti-inflammatory molecules.

The application discloses application of TAPI-1 in preparation of a drug for treating dry age-related macular degeneration, and belongs to the technical field of biological medicine. A dry age-related macular degeneration mouse model is constructed by using sodium iodate, and a TAPI-1 solution is injected into the vitreous body for treatment, and structural examination and histopathological examination are conducted on the mouse. The experimental results show that, compared with the control group, the retinal choroid structure of the mouse treated by TAPI-1 is more complete, the fundus lesion area is less, the damage degree of the pigment epithelium and the photoreceptor cell is lighter, and the expression level of the inflammatory molecules in the ocular tissue is lower, and the treatment effect is significant. The application firstly proposes that TAPI-1 is used for preparing a drug for treating and / or preventing dry age-related macular degeneration, a new treatment strategy is provided for the dry age-related macular degeneration, and the application has a wide application prospect.

The application relates to a compound for improving vascular endothelial cell function, a preparation method and application thereof. The compound is prepared by taking tyrosol, dopamine, substituted cinnamic acid or 5-carboxyl pentyl-triphenyl phosphonium bromide as a starting material, and then performing amidation or esterification reaction with adamantylamine and adamantane acid. The compound has a significant inhibitory effect on the inflammation reaction of endothelial cells induced by palmitate (PA) as an anti-inflammatory molecule, can be used for preparing drugs for hyperlipidemia and related cardiovascular diseases, treating vascular endothelial injury diseases, treating hyperlipidemia, atherosclerosis and related cardiovascular diseases, and has the potential of being developed into innovative drugs for treating hyperlipidemia, atherosclerosis and related cardiovascular diseases with high efficiency and low toxicity.

This invention discloses a dynamic covalent colloidal adhesive material, its preparation method, and its applications, belonging to the field of biomedical materials. This invention provides a novel method for constructing dynamic covalent colloidal adhesives (DCCGs) based on a reaction-induced self-assembly (RISA) strategy, and uses the prepared DCCGs for the combined treatment of periodontal inflammation and tooth demineralization. Experimental results show that the DCCGs prepared by this invention can adhere efficiently and exhibit outstanding functions in scavenging free radicals and pro-inflammatory molecules, inhibiting bacterial colonization, and promoting tooth remineralization. The DCCGs prepared by this invention can meet the needs of synergistic anti-inflammatory and promineralization treatment in oral cavity, providing a novel multifunctional integrated material for the treatment of periodontal diseases and laying the foundation for multi-disease co-treatment strategies.

The present invention relates to transdermal devices comprising prodrugs of anti-pyretic, analgesic, or anti-inflammatory molecules, methods of making such devices, and methods of use thereof for treating, preventing, minimizing, and / or diminishing fever or pain.

A genetically modified E. coli bacterium is provided where the bacterium expresses a microbial anti-inflammatory molecule (MAM) protein. In one embodiment, the bacterium is a probiotic. In another embodiment, the bacterium is modified is E. coli Nissle 1917. In one embodiment, the MAM protein has a sequence of [SEQ ID NO: 1]. In another embodiment, the bacterium expresses a plasmid having a sequence of [SEQ ID NO: 2].

The presently disclosed subject matter relates to the field of digital therapeutics to decrease pro-inflammatory molecules such as cytokines and chemokines. A primary mode of delivering the digital therapeutics is using sensory means comprising: sensory inhibition, sensory substitution, sensory integration, or a combination thereof. The invention also provides combination therapies that comprise digital interventions together with non-digital interventions such as medicinal agents.

The application discloses an application of inducing sputum CC16 as a prediction marker of COPD severity and eosinophil subtype. The application finds that the expression of CC16 in induced sputum of mild and moderate COPD patients and severe and very severe COPD patients has significant difference by detecting and analyzing various inflammatory molecules in induced sputum, and can distinguish eosinophilic COPD. The application establishes a regression model based on FEV1pred% and the relative expression level of CC16 mRNA, and the model has good sensitivity, specificity and accuracy. Therefore, the mRNA level of induced sputum CC16 has good application prospect for evaluating the severity of COPD and diagnosing the eosinophil subtype. The application can evaluate the severity of COPD and diagnose the eosinophil subtype in a more simple way, and based on the characteristics of the biomarker, a more reliable non-invasive kit can be prepared.

The invention discloses a hypoallergenic aluminum phosphate agent for human as well as a preparation method and application thereof, and belongs to the technical field of pharmaceutic adjuvants. The aluminum phosphate agent is of a core-shell structure, the core is aluminum phosphate nanoparticles, the shell layer is a hydroxypropyl chitosan-polyethylene glycol cross-linked compound, and a modification layer is loaded with vitamin E succinate; the particle size of the composite particle is 80-150nm, the zeta potential is-8 to-3mV, and the composite particle comprises the following components in percentage by mass: 75-80% of aluminum phosphate, 17-22% of cross-linked compound, 0.5-2% of anti-inflammatory molecule and 0-3% of optional mannitol stabilizer. The preparation method adopts a precipitation-ultrasonic-assisted microfluidic modification-freeze-drying process. The aluminum phosphate agent can be used for human hypoallergenic vaccine adjuvants or drug carriers, and the problems that traditional aluminum phosphate is high in allergenicity and single in function are solved.